Tonix Pharmaceuticals Holding Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 142

Employees

  • Stock Symbol
  • TNXP

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $2.88
  • (As of Monday Closing)

Tonix Pharmaceuticals Holding General Information

Description

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 26 Main Street
  • Suite 101
  • Chatham, NJ 07928
  • United States
+1 (862)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 26 Main Street
  • Suite 101
  • Chatham, NJ 07928
  • United States
+1 (862)

Tonix Pharmaceuticals Holding Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tonix Pharmaceuticals Holding Stock Performance

As of 16-Nov-2026, Tonix Pharmaceuticals Holding’s stock price is $2.88. Its current market cap is $56M with 19.4M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.88 $3.01 $2.81 - $20.56 $56M 19.4M 802K -$12.22

Tonix Pharmaceuticals Holding Financials Summary

As of 30-Sep-2026, Tonix Pharmaceuticals Holding has a trailing 12-month revenue of $43M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (7,909) 10,120 42,097 17,858
Revenue 43,046 13,107 10,094 7,768
EBITDA (184,164) (126,153) (125,403) (112,367)
Net Income (180,985) (124,021) (130,036) (116,658)
Total Assets 242,426 277,171 162,890 154,457
Total Debt 1,253 1,309 8,119 9,813
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Tonix Pharmaceuticals Holding Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Tonix Pharmaceuticals Holding‘s full profile, request access.

Request a free trial

Tonix Pharmaceuticals Holding Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therap
Drug Discovery
Chatham, NJ
142 As of 2025

Cambridge, MA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tonix Pharmaceuticals Holding Competitors (38)

One of Tonix Pharmaceuticals Holding’s 38 competitors is Seres Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seres Therapeutics Formerly VC-backed Cambridge, MA
Cognition Therapeutics Formerly VC-backed New York, NY
Alector Formerly VC-backed South San Francisco, CA
Neurelis Venture Capital-Backed San Diego, CA
Dogwood Therapeutics Formerly VC-backed Alpharetta, GA
You’re viewing 5 of 38 competitors. Get the full list »

Tonix Pharmaceuticals Holding Patents

Tonix Pharmaceuticals Holding Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025199179-A2 Oxytocin peptide analogs Pending 18-Mar-2024
WO-2025199179-A3 Oxytocin peptide analogs Pending 18-Mar-2024
WO-2025160302-A1 Cyclobenzaprine treatment for acute stress reaction or acute stress disorder Pending 25-Jan-2024
WO-2025137348-A1 Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile Inactive 19-Dec-2023
US-20250322926-A1 Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia Pending 19-Dec-2023 G16H20/10
To view Tonix Pharmaceuticals Holding’s complete patent history, request access »

Tonix Pharmaceuticals Holding Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tonix Pharmaceuticals Holding Investments & Acquisitions (7)

Tonix Pharmaceuticals Holding’s most recent deal was a Corporate Asset Purchase with Dr. Reddy's (Neurology Migraine Products) for . The deal was made on 30-Jun-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dr. Reddy's (Neurology Migraine Products) 30-Jun-2023 Corporate Asset Purchase Buildings and Property
Healion Bio 02-Feb-2023 Merger/Acquisition Drug Discovery
Southern Research (Infectious Disease R&D Facility in Frederick, Maryland) 04-Oct-2021 Corporate Asset Purchase Buildings and Property
Katana Pharmaceuticals (Assets Related To Insulin Resistance in Chatham, New Jersey) 22-Dec-2020 Corporate Asset Purchase Buildings and Property
Trigemina (Non-Addictive Migraine and Pain Treatment Programs in Moraga, California) 11-Jun-2020 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Tonix Pharmaceuticals Holding ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.12 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Tonix Pharmaceuticals Holding’s complete esg history, request access »

Tonix Pharmaceuticals Holding FAQs

  • When was Tonix Pharmaceuticals Holding founded?

    Tonix Pharmaceuticals Holding was founded in 2007.

  • Where is Tonix Pharmaceuticals Holding headquartered?

    Tonix Pharmaceuticals Holding is headquartered in Chatham, NJ.

  • What is the size of Tonix Pharmaceuticals Holding?

    Tonix Pharmaceuticals Holding has 142 total employees.

  • What industry is Tonix Pharmaceuticals Holding in?

    Tonix Pharmaceuticals Holding’s primary industry is Drug Discovery.

  • Is Tonix Pharmaceuticals Holding a private or public company?

    Tonix Pharmaceuticals Holding is a Public company.

  • What is Tonix Pharmaceuticals Holding’s stock symbol?

    The ticker symbol for Tonix Pharmaceuticals Holding is TNXP.

  • What is the current stock price of Tonix Pharmaceuticals Holding?

    As of 16-Nov-2026 the stock price of Tonix Pharmaceuticals Holding is $2.88.

  • What is the current market cap of Tonix Pharmaceuticals Holding?

    The current market capitalization of Tonix Pharmaceuticals Holding is $56M.

  • What is Tonix Pharmaceuticals Holding’s current revenue?

    The trailing twelve month revenue for Tonix Pharmaceuticals Holding is $43M.

  • Who are Tonix Pharmaceuticals Holding’s competitors?

    Seres Therapeutics, Cognition Therapeutics, Alector, Neurelis, and Dogwood Therapeutics are some of the 38 competitors of Tonix Pharmaceuticals Holding.

  • What is Tonix Pharmaceuticals Holding’s annual earnings per share (EPS)?

    Tonix Pharmaceuticals Holding’s EPS for 12 months was -$12.22.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process